【摘要】 目的:评价米氮平联用碳酸锂治疗双相抑郁的疗效及其安全性。方法:将符合CCMD-3(中国精神障碍分类第三版)双相抑郁诊断标准的66例门诊或住院病人随机分为2组,每组33例,分别服用米氮平联用碳酸锂,或丙米嗪联用碳酸锂。试验时间为6周,以HAMD(汉密尔顿抑郁问卷)和CGI(临床总体印象问卷)评估两组的疗效,以TESS(治疗中出现的不良反应量表)评定安全性。结果:两组疗效差异无显著性,米氮平组的不良反应发生率明显低于丙米嗪组,差异有显著性。结论:米氮平治疗双相抑郁起效快,疗效肯定,副作用小,依从性好,联用锂盐能较好提高双相抑郁的缓解率,降低转躁率。更多还原

【Abstract】 Objective: To evaluate the efficacy and safety of mirtazapine combined with lithium carbonate on bipolar depression. Methods: 66 patients with bipolar depression, diagnosed with CCMD-3 (Chinese Classification of Mental Disorders, 3rd Edition), were randomized to take mirtazapine combined with lithium carbonate,or imipramine combined with lithium carbonate. HAMD, CGI and TESS were used to evaluate the efficacy and safety of the two groups. Results: There was no significant difference of the therapeutic effect between the two groups. The side effects in mirtazapine group were significantly more than that of imipramine group. Conclusions: The effect of mirtazapine combined with lithium carbonate on bipolar depression was rapid and valid, the side effects of mirtazapine was less and milder than imipramine combined with lithium carbonate. Combination of mirtazapine and lithium carbonate could increase remission rate of bipolar depression and decrease mania-switching rate.更多还原